41
st Annual Meeting of September 5-6, 2020 the Endocrine Society and the Diabetes Association of the R.O.C. (Taiwan)
The
PE-1 CLINICAL EFFICACY OF SANDOSTATIN LAR 20 MG IN PATIENTS WITH ACROMEGALY AFTER INCOMPLETE SURGERY TZU-CHING HUNG, WAN-CHI CHUANG, WEI-CHENG CHANG, 1CHIH-HSUN CHU Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Veterans General HosPital, Kaohsiung, Taiwan; 1Department of Nursing, School of Nursing, Fooyin University, Kaohsiung, Taiwan.
Background: The objective of this study is to retrospectively survey the efficacy of sandostatin LAR 20mg in patients with acromegaly after incomplete surgery. Methods: From October 2015 to February 2019, there were eleven subjects (4 male, 7 female) who with pituitary adenoma and complicated with acromegaly receiving operation, but the growth hormone level remained above 1 μg/l. The mean age were 55.8 yr (range from 37 to 74 yr), Nine patient (82%) was macroadenoma. There were eight patients (73%) complicated with diabetes, one with prediabetes, only two (18%) without glycemic abnormalities. They were all received sandostatin LAR 20mg injection per month. Results: The mean duration of treatment were 26.2 ± 12.5 months (range from 7 to 47 months). The baseline levels of growth hormone were 3.3 ± 1.8μg/l, IGF-1 were 628.8 ± 197.2 ng/ml. After sandostatin LAR 20mg management, the latest levels of growth hormone decreased to 0.95 ± 0.95μg/ l (∆ 68%, P = 0.001), levels of IGF-1 decreased to 197.2 ± 64.2 ng/ml (∆ 61%, P=0.002). Nine patients (82%) with levels of growth hormone < 1 μg/l. Nine patients (82%) with IGF-1 in normal values. There were seven patients (64%) achieved growth hormone levels < 1 μg/l combined with normalization of IGF-1 values. Conclusion: In patients with acromegaly after incomplete surgery. Sandostatin LAR 20mg injection per month is an effective treatment for most of them.
118
